AWAlan Wacquiez

Alan Wacquiez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alan Wacquiez has a total of 115 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mitochondrial OXPHOS restricts SARS-CoV-2 replication

    by Yentli E. Soto Albrecht, Ryan M. Morrow, Devin Kenney, Arnold Z. Olali, Alan Wacquiez, Nader Chehadeh, Zimu Cen, Jeffrey A. Haltom, Ian Chen, Sujata S. Ranshing, et al.

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rewires host metabolism to optimize virus production. Although glycolysis is necessary for virus production, the importance of mitochondrial oxidative phosphorylation (OXPHOS) is unknown. The mitochondrial DNA (mtDNA) codes for 13 critical OXPHOS polypeptides plus the 22 transfer RNAs (tRNAs) and 2 ribosomal RNAs (rRNAs) for mitochondrial protein synthesis. We found an ∼5- to 100-fold greater SARS-CoV-2 virus production in infected human ACE2-expressing A549 lung cells when OXPHOS was inhibited by mtDNA depletion (ρ 0 cells), inhibition of mitochondrial translation with chloramphenicol (CAP), or chemical inhibition of OXPHOS complexes. OXPHOS inhibition led to a marked increase in the size and distribution of viral replication centers and accelerated the production and release of infectious particles, occurring ∼2 hours earlier than in parental A549-ACE2 (wild type) cells. Subsequently, we found that increased glycolytic capacity was required for enhanced viral replication whereas differences in innate immune pathway activation were not. Reintroduction of mtDNA from a well-defined maternal lineage into the ρ 0 cells reinstated OXPHOS, impaired SARS-CoV-2 replication, and reversed associated viral and glycolytic correlates. Thus, metabolic balance regulates SARS-CoV-2 replication, with OXPHOS exerting an antiviral effect.


  • Caractérisation moléculaire du domaine de liaison à l'ARN de la protéine non-structurale 1 (NS1) des virus influenza A lors de l'interaction avec un ARN double-brin de haute affinité contenant des séquences sélectionnées in vitro

    by Alan Wacquiez

    Les virus influenza A (IVA) sont un problème persistant au niveau mondial et notre arsenal thérapeutique actuel n’est pas à l’abri de résistances. La protéine non-structurale 1 (NS1) des IVA limite la réponse antivirale en ciblant majoritairement la réponse interféron (IFN). Réputée pour ses interactions avec de nombreuses protéines cellulaires (Han et al., 2019), NS1 interagit aussi avec des ARN double-brin (dsRNA) et des ARN viraux arborant des motifs conservés du virus (Marc et al., 2013). La double-substitution R38A-K41A, qui invalide son domaine de liaison à l’ARN (RBD), est connue pour abolir la virulence et réduire fortement la multiplication virale, soulignant l’importance du RBD dans les fonctions de NS1 (Trapp et al., 2018) et justifiant le besoin de développer de nouveaux antiviraux ciblant l’interface RBD/dsRNA (Engel, 2013).Marc et al. (2013) ont identifié par SELEX des aptamères d’ARN de haute affinité pour NS1 qui arborent des séquences virales (les motifs AGCAAAAG et UGAUUGAAG) et une séquence canonique de site donneur d’épissage des ARNm cellulaires (le motif double-brin GUAAC). Au cours de ce projet, j’ai montré en mutant spécifiquement dans le segment NS la séquence virale UGAUUGAAG qui est hautement conservée dans la 3’-UTR des ARNm de NS1 que cette séquence n’était pas essentielle au bon déroulement du cycle viral à la différence de la séquence virale AGCAAAAG qui assure un rôle fonctionnel en tant que promoteur de la polymérase virale (de la Luna et al., 1995 ; Marión et al., 1997). En caractérisant par gel retard les éléments de l’ARN et du RBD de NS1 qui sont essentiels à la formation de complexes RBD/dsRNA de haute affinité, j’ai montré que de tels complexes peuvent être observés lorsque le dsRNA (i) fait un minimum de 15 paires de bases et (ii) contient au moins un motif double-brin GUAAC en position distale de la structure tige-boucle. J’ai également mis en évidence une coopération du motif viral AGCAAAAG dans l’interaction du dsRNA avec le RBD de NS1 (Wacquiez et al., en révision). Cette caractérisation nous a permis de concevoir la sonde ARN AWFC01 qui forme des complexes de haute affinité avec le RBD de toutes les NS1 testées. AWFC01 est également 100 fois plus affin pour le RBD de NS1 que ne l’est le dsRNA CHENG utilisé pour résoudre la première structure cristallographie du complexe RBD/dsRNA (Cheng et al., 2009).L’approche structurale que nous avons menée par cristallographie sur AWFC01 indique l’importance des acides aminés contenus dans les hélices 2 et 2’, en particulier R38, dans l’interaction avec les ions phosphates et la fonction 2’OH des riboses de l’ARN, témoignant ainsi d’une reconnaissance spécifique de l’ARN par le RBD de NS1. De façon remarquable, le RBD de NS1, qui ne reconnaît directement ni les nucléobases de l’ARN ni celles des motifs double-brin GUAAC dans AWFC01, induit une légère courbure de AWFC01 (Wacquiez et al., en révision) sans grande modification des paramètres hélicoïdaux de l’ARN. Nos résultats semblent indiquer que le RBD de NS1 se comporte comme le facteur TFIIIA de Xenopus laevis, la protéine B2 du virus Flock House, la protéine NS3 du virus du riz à feuilles blanches ou encore la protéine VP35 du virus Ebola, qui interagissent avec le squelette ribose-phosphate de l’ARN sans en reconnaître les bases spécifiquement. Mots-clés : virus influenza A ; protéine non-structurale 1 ; Domaine de liaison à l’ARN ; Domaine effecteur ; ARN double-brin ; SELEX ; séquence virale AGCAAAAG ; séquence virale UGAUUGAAG ; motif double-brin GUAAC ; ARN AWFC01 ; ARN CHENG ; Cristallographie à rayons X ; courbure de l’ARN.

  • Open Access

    Cis-aconitate therapy protects against influenza mortality by dual targeting of viral polymerase and ERK/AKT/NF-κB signaling

    by Adeline Cezard, Déborah Brea-Diakite, Virginie Vasseur, Alan Wacquiez, Loic Gonzalez, Ronan Le Goffic, Bruno Da Costa, Ambre Tinard, Delphine Fouquenet, Séverine Heumel, et al.

    The influenza virus poses a significant global health challenge, causing approximately 500,000 deaths annually. Its ability to evade antiviral treatments and vaccine-induced immunity underscores the need for novel therapeutic approaches. Our study identifies cis -aconitate ( cis -aco), a mitochondria-derived metabolite, as a potent dual-action agent against influenza, independently of its metabolic derivative, itaconate. Cis -aco impairs viral polymerase activity, resulting in decreased viral mRNA expression and protein synthesis, as observed for the influenza A/Scotland/20/74 (H3N2) strain. This antiviral effect was further confirmed across multiple influenza A and B strains, as well as in ex vivo human airway and lung organotypic models. Beyond its antiviral properties, cis- aco exhibits potent anti-inflammatory effects, disrupting key inflammatory cascades and reducing the secretion of inflammatory mediators. In a mouse model of influenza pneumonia, cis -aco mitigates viral replication, inflammation, and immune cell activation, significantly improving survival. Notably, its efficacy persists even when administered at later stages of infection, when oseltamivir/Tamiflu® is no longer effective. These findings position cis -aco as a promising influenza treatment, combining antiviral and anti-inflammatory benefits within a clinically relevant timeframe.


  • Structure-Guided Design of Potent and Selective Covalent Inhibitors Targeting the SARS-CoV-2 Papain-like Protease

    by Mona Sharafi, Wei Pin Teh, Jeremy Green, Paul S. Charifson, Jinhua Wang, Orville A. Pemberton, Amanda M. Nevins, Ming Lye, Xiaoxi Liu, Anthony C. Varca, et al.

    The COVID-19 pandemic led to numerous initiatives to create antiviral medications and vaccines for the treatment and prevention of infections. However, the need remains for new therapies with distinct mechanisms of action from current treatment of COVID-19 infections as well as for future pandemic preparedness. SARS-CoV-2 papain-like protease (PLpro) is a cysteine protease that cleaves the viral polyprotein and possesses deubiquitylase (DUB) and deISGylase activity that can act on host proteins. Here, we report the structure-guided development of covalent inhibitors of SARS-CoV-2 PLpro that possess low nanomolar to subnanomolar antiviral activity in cell assays and inhibit viral replication in a mouse model of SARS-CoV-2 infection. The most potent inhibitors contain N-propargylamide electrophiles, a relatively inert warhead not typically featured in covalent protease inhibitors. These findings provide a foundation for further discovery and optimization of covalent PLpro inhibitors that could lead to future antiviral therapeutics.


  • Open Access

    Cis -aconitate therapy protects against influenza mortality by dual targeting of viral polymerase and ERK/AKT/NF-κB signaling

    by Adeline Cezard, Déborah Brea-Diakite, Virginie Vasseur, Alan Wacquiez, Loic Gonzalez, Ronan Le Goffic, Bruno Da Costa, Delphine Fouquenet, Severine Heumel, Arnaud Machelart, et al.

    Influenza virus poses a significant global health challenge, causing approximately 500,000 deaths annually. Its ability to evade antiviral treatments and vaccine-induced immunity underscores the need for novel therapeutic approaches. Our study identifies cis -aconitate ( cis -aco), a mitochondria-derived metabolite, as a potent dual-action agent against influenza, independently of its metabolic derivative, itaconate. Cis -aco impairs viral polymerase activity, suppressing viral mRNA expression and protein synthesis to inhibit replication across a range of influenza subtypes. This antiviral efficacy is confirmed in ex vivo human airway and lung organotypic models. Beyond its antiviral properties, cis-aco exhibits potent anti-inflammatory effects, disrupting key inflammatory cascades and reducing the secretion of inflammatory mediators. In a mouse model of influenza pneumonia, cis -aco mitigates viral replication, inflammation, and immune cell activation, significantly improving survival. Notably, its efficacy persists even when administered at later stages of infection, when oseltamivir/Tamiflu® is no longer effective. These findings position cis -aco as a promising influenza treatment, combining antiviral and anti-inflammatory benefits within a clinically relevant timeframe.


  • Amidino-rocaglates (ADRs), a class of synthetic rocaglates, are potent inhibitors of SARS-CoV-2 replication through inhibition of viral protein synthesis

    by Patrick T. Keiser, Wenhan Zhang, Michael Ricca, Alan Wacquiez, Autumn Grimins, Regina Cencic, J.J. Patten, Pranav Shah, Elias Padilha, John H. Connor, et al.


  • Open Access

    Host succinate inhibits influenza virus infection through succinylation and nuclear retention of the viral nucleoprotein

    by Antoine Guillon, Deborah Brea‐Diakite, Adeline Cezard, Alan Wacquiez, Thomas Baranek, Jérôme Bourgeais, Frédéric Picou, Virginie Vasseur, Léa Meyer, Christophe Chevalier, et al.

    Influenza virus infection causes considerable morbidity and mortality, but current therapies have limited efficacy. We hypothesized that investigating the metabolic signaling during infection may help to design innovative antiviral approaches. Using bronchoalveolar lavages of infected mice, we here demonstrate that influenza virus induces a major reprogramming of lung metabolism. We focused on mitochondria‐derived succinate that accumulated both in the respiratory fluids of virus‐challenged mice and of patients with influenza pneumonia. Notably, succinate displays a potent antiviral activity in vitro as it inhibits the multiplication of influenza A/H1N1 and A/H3N2 strains and strongly decreases virus‐triggered metabolic perturbations and inflammatory responses. Moreover, mice receiving succinate intranasally showed reduced viral loads in lungs and increased survival compared to control animals. The antiviral mechanism involves a succinate‐dependent posttranslational modification, that is, succinylation, of the viral nucleoprotein at the highly conserved K87 residue. Succinylation of viral nucleoprotein altered its electrostatic interactions with viral RNA and further impaired the trafficking of viral ribonucleoprotein complexes. The finding that succinate efficiently disrupts the influenza replication cycle opens up new avenues for improved treatment of influenza pneumonia.